AIQ Sponsored Imaging Innovations Webinar
September 20, 2022 – AIQ Solutions sponsored a new webinar titled “Discovering Amyloidosis: how AI Imaging Application Shed Light on Rare Disease” on October 20th at 12pm – 1pm ET.
Systemic amyloidosis is a rare disease resulting in organ malfunction from build-up of the protein amyloid. Detection and quantification of amyloid burden in the body is an unmet clinical need with approximately 80% of patients undiagnosed.
Dr. Jonathan Wall of the University of Tennessee, together with AIQ Solutions, used an AI-driven, fully automated 3D segmentation and quantitation of a novel radiotracer to quantify amyloid burden in patients’ hearts and other organs.
This automated approach to image analysis could be an invaluable tool for novice readers, especially to quantify disease burden over time without introducing reader bias. This case study was in the rare disease amyloidosis, but this method has broad implications for meeting unmet needs in metastatic cancers and other complex diseases.
In this webinar, the scientists will share:
- Understanding amyloidosis and its limitations in diagnosis and treatment options.
- Overview of radiotracer options in identification and treatment response assessment
- Introduction and comparison of 2D and 3D quantitation methods
- Learn how to use AI driven imaging technologies for case studies
- Discuss benefits of 3D automated quantitation
- Lessons learned on applying innovative AI technology
About the Speakers:
Jonathan Wall, PhD is a tenured Distinguished Professor and Director of Research at the University of Tennessee Graduate School of Medicine, Knoxville (UTGSM). He now serves as Director of the NIH-funded Amyloidosis and Cancer Theranostics Program at UTGSM, where the focus remains on the development and translation of biological agents for imaging and treatment of systemic amyloid diseases. He has over 100 publications and 29 issued US and international patents. He graduated from the University of Essex with a PhD in Biological Chemistry and Biophysics.
AIQ Solutions Joined Lucem Health™ On the Front Lines of Healthcare
June 9, 2022 – Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partner program designed to move clinical AI/ML innovation to the front lines of healthcare. The Collaborative will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models. AIQ Solutions is one of the eleven founding innovation collaborative members.
Read the full news (here).
About Lucem Health
Lucem Health™, launched with Mayo Clinic along with investing partners Commure (a General Catalyst company) and Rally Ventures, empowers healthcare visionaries to quickly bring AI powered insights to the point of care. To learn more, click here.
AIQ Solutions Will Speak at the Precision Medicine World Conference 2022
May 18, 2022 – AIQ President & CEO, Eric Horler was invited to speak at the Precision Medicine World Conference (PMWC) 2022 in Silicon Valley on June 30 at 11:45am PT. Eric’s presentation was part of Track 2 on “Technical Advancements in Clinical Machine Learning – What’s New in 2021”. To request a meeting to learn more about AIQ Solutions and our novel biomarkers for therapy optimization, contact us (here).
PMWC is the largest and original annual conference dedicated to precision medicine. To learn more, click (here).
AIQ Solutions Will Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver
May 3, 2022 – AIQ’s collaboration with researchers at University of Wisconsin – Madison will be highlighted in an oral presentation by AIQ Lead Project Scientist, Amy J Weisman, PhD at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Vancouver, Canada on June 11-14.
The abstract entitled, Automated Evaluation of Disease on 68Ga-DOTATATE PET/CT Images for Long-term Lesion Tracking on 177Lu-DOTATATE Therapy will be presented on Sunday, June 12th at 12:30 pm PT.
To request a copy of the presentation, (click here).
AIQ Solutions President & CEO Eric Horler Speaker at BIO International Convention 2022
April 28, 2022 – President & CEO, Eric Horler, will present “Imaging biomarkers to better evaluate and predict treatment response for complex diseases.” at the Biotechnology Innovation Organization (BIO) International Convention 2022 in San Diego, California June 13th through 16th, 2022. Join his speech at the Company Presentation Theater 2 on Wednesday, June 15, 2022 at 4:00 pm- 4:15 pm PT.
About Biotechnology Innovation Organization
BIO is committed to speaking up for the millions of families around the globe who depend upon our success. We will drive a revolution that aims to cure patients, protects our climate, and nourishes humanity. To learn more, click (here).
AIQ Solutions Awarded $2M by the National Cancer Institute
April 26, 2022 – AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance development and commercialization of a novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy.
Visit AIQ Solutions at ASCO Annual Meeting in Chicago
April 12, 2022 – AIQ will be exhibiting the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois from June 4th through 6th. Visit our kiosk at IH#22 to learn more about AIQ Solutions, and our treatment response quantification and prediction technology. To schedule a meeting with us in advance, contact us (here).
AIQ Solutions at the American Association for Cancer Research Annual Meeting
March 10, 2022 – AIQ Solutions will be attending the Annual Meeting of American Association for Cancer Research (AACR) in New Orleans, Louisiana from April 8th through 13th, 2022. Visit our booth #923 to learn more about AIQ Solutions, and our treatment response quantification and prediction technology.
About the AACR
The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. To learn more, click (here).
AIQ Solutions at Immuno-Oncology 360° 2022
February 10, 2022 – AIQ Solutions will be attending Immuno-Oncology 360° from March 16th through 18th, 2022 in New York Marriott Brooklyn Bridge. To request a meeting to learn more about AIQ Solutions, and our treatment response quantification and prediction technology, contact us (here).
Visit AIQ Solutions at 2022 ASCO Genitourinary Cancers Symposium
January 14, 2022 – AIQ will be exhibiting at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California on February 17th through 19th, 2022. Visit our booth #36 to learn more about our imaging services for clinical trials and patient management. To schedule a meeting, click (here).
Visit AIQ Solutions at 2021 ASCO Genitourinary Cancers Symposium
January 14, 2021 – AIQ will be attending the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium from February 11th through 13th, 2021 in a virtual format. Request a meeting to learn more about AIQ Solutions, and our treatment response quantification and prediction technology. Contact us (here).
AIQ Solutions at J.P. Morgan 39th Annual Healthcare Conference 2021 Digital
January 01, 2021 – AIQ Solutions will be attending J.P. Morgan 39th Annual Healthcare Conference from January 11th through January 15th, 2021, in a virtual format. Request a meeting to learn more about AIQ Solutions and our treatment response quantification and prediction technology. Contact us (here).
AIQ Announced Partnership with Flywheel
September 28, 2020 – Flywheel and AIQ Solutions recently announced a partnership to offer a data management and analysis solution to increase clinicians’ and researchers’ understanding of treatment response for complex diseases that include the largest research area of oncology. The combination of Flywheel’s cloud-scale data management and collaboration platform along with the powerful AIQ technology will provide a scalable solution for improved patient management and the overall delivery of accurate data for the therapeutic area.
Flywheel is the pioneering medical imaging data and AI platform powering healthcare innovation through streamlined data aggregation, curation and management. To learn more, (click here).